Older patients with CKD who started allopurinol at higher risk of severe cutaneous reaction
Older patients with CKD who started allopurinol at >100 mg/d versus <100 mg/d were twice as likely to visit a hospital with a severe cutaneous reaction in the next 180 days suggests a recent study published in the American Journal of Kidney Disease.
Allopurinol should be started at lower doses in patients with chronic kidney disease (CKD) to avoid adverse effects. They examined the risk of severe cutaneous reactions in older adults with CKD who were newly prescribed allopurinol at varying doses.
Population-based cohort study using linked health care databases was conducted. Patients in Ontario, Canada (2008-2019) aged ≥66 years, with an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2, and who were new users of allopurinol. A new prescription for allopurinol >100 mg/d versus a dose ≤100 mg/d. The primary outcome was a hospital visit with a severe cutaneous reaction within 180 days of starting allopurinol. Secondary outcomes included all-cause hospitalisation and all-cause mortality.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.